Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection.
COVID-19
T cell exhaustion/senescence
convalescents
full spectral cytometry
immune system
inflammation resolution
long COVID
post-acute COVID-syndrome (PACS)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
02
2022
accepted:
22
04
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
Several COVID-19 convalescents suffer from the post-acute COVID-syndrome (PACS)/long COVID, with symptoms that include fatigue, dyspnea, pulmonary fibrosis, cognitive dysfunctions or even stroke. Given the scale of the worldwide infections, the long-term recovery and the integrative health-care in the nearest future, it is critical to understand the cellular and molecular mechanisms as well as possible predictors of the longitudinal post-COVID-19 responses in convalescent individuals. The immune system and T cell alterations are proposed as drivers of post-acute COVID syndrome. However, despite the number of studies on COVID-19, many of them addressed only the severe convalescents or the short-term responses. Here, we performed longitudinal studies of mild, moderate and severe COVID-19-convalescent patients, at two time points (3 and 6 months from the infection), to assess the dynamics of T cells immune landscape, integrated with patients-reported symptoms. We show that alterations among T cell subsets exhibit different, severity- and time-dependent dynamics, that in severe convalescents result in a polarization towards an exhausted/senescent state of CD4+ and CD8+ T cells and perturbances in CD4+ Tregs. In particular, CD8+ T cells exhibit a high proportion of CD57+ terminal effector cells, together with significant decrease of naïve cell population, augmented granzyme B and IFN-γ production and unresolved inflammation 6 months after infection. Mild convalescents showed increased naïve, and decreased central memory and effector memory CD4+ Treg subsets. Patients from all severity groups can be predisposed to the long COVID symptoms, and fatigue and cognitive dysfunctions are not necessarily related to exhausted/senescent state and T cell dysfunctions, as well as unresolved inflammation that was found only in severe convalescents. In conclusion, the post-COVID-19 functional remodeling of T cells could be seen as a two-step process, leading to distinct convalescent immune states at 6 months after infection. Our data imply that attenuation of the functional polarization together with blocking granzyme B and IFN-γ in CD8+ cells might influence post-COVID alterations in severe convalescents. However, either the search for long COVID predictors or any treatment to prevent PACS and further complications is mandatory in all patients with SARS-CoV-2 infection, and not only in those suffering from severe COVID-19.
Identifiants
pubmed: 35757700
doi: 10.3389/fimmu.2022.886431
pmc: PMC9226563
doi:
Substances chimiques
Granzymes
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
886431Informations de copyright
Copyright © 2022 Wiech, Chroscicki, Swatler, Stepnik, De Biasi, Hampel, Brewinska-Olchowik, Maliszewska, Sklinda, Durlik, Wierzba, Cossarizza and Piwocka.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Brain. 2021 Dec 31;144(12):3576-3588
pubmed: 34398188
Nat Rev Immunol. 2021 Apr;21(4):245-256
pubmed: 33723416
J Immunol. 2002 Jun 1;168(11):5538-50
pubmed: 12023349
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Eur J Immunol. 2021 Dec;51(12):2708-3145
pubmed: 34910301
Front Immunol. 2020 Oct 14;11:580237
pubmed: 33154753
Viruses. 2021 Nov 26;13(12):
pubmed: 34960645
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Immunology. 2011 Sep;134(1):17-32
pubmed: 21711350
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Nat Commun. 2021 Jan 12;12(1):302
pubmed: 33436591
Vaccines (Basel). 2021 May 12;9(5):
pubmed: 34066007
Trends Pharmacol Sci. 2015 Nov;36(11):737-755
pubmed: 26478210
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
Proc Natl Acad Sci U S A. 2021 Sep 14;118(37):
pubmed: 34433692
Front Microbiol. 2021 Jun 23;12:698169
pubmed: 34248921
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Aging Dis. 2021 Oct 1;12(7):1545-1553
pubmed: 34631206
Arch Med Res. 2021 Aug;52(6):575-581
pubmed: 33962805
J Intensive Care. 2021 Dec 20;9(1):76
pubmed: 34930468
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Pathogens. 2021 Oct 30;10(11):
pubmed: 34832564
Front Immunol. 2021 Sep 29;12:748097
pubmed: 34659245
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Immunity. 2020 Dec 15;53(6):1296-1314.e9
pubmed: 33296687
AIDS. 2020 Dec 1;34(15):2169-2185
pubmed: 32910071
Front Immunol. 2021 Oct 21;12:769059
pubmed: 34745145
JCI Insight. 2021 Dec 22;6(24):
pubmed: 34784300
Trends Immunol. 2009 Jul;30(7):306-12
pubmed: 19540809
J Invest Dermatol. 2021 Mar;141(3):575-585
pubmed: 32738245
Nat Commun. 2021 Jul 29;12(1):4677
pubmed: 34326336
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
J Virol. 2020 Dec 23;:
pubmed: 33361429
EMBO Mol Med. 2020 Dec 7;12(12):e13001
pubmed: 33078545
Cells. 2020 Dec 05;9(12):
pubmed: 33291439
Cell. 2022 Mar 3;185(5):881-895.e20
pubmed: 35216672
Cells. 2021 Jun 19;10(6):
pubmed: 34205262
J Clin Invest. 2020 Dec 1;130(12):6588-6599
pubmed: 32841212
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33119547
Front Immunol. 2016 Apr 26;7:160
pubmed: 27199985
Nat Immunol. 2022 Feb;23(2):210-216
pubmed: 35027728
Nat Commun. 2021 May 10;12(1):2593
pubmed: 33972535
Eur J Immunol. 2020 Sep;50(9):1283-1294
pubmed: 32910469
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Glob Adv Health Med. 2021 Nov 16;10:21649561211056597
pubmed: 34820152
J Exp Med. 2021 Feb 1;218(2):
pubmed: 33119033
Eur J Immunol. 2016 Oct;46(10):2286-2301
pubmed: 27595500
J Neurol. 2021 Sep;268(9):3059-3071
pubmed: 33486564
Cell Rep. 2021 Aug 10;36(6):109518
pubmed: 34358460
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Int J Med Sci. 2018 Apr 3;15(7):666-673
pubmed: 29910670
BMC Med. 2022 Jan 14;20(1):26
pubmed: 35027067
Allergy. 2021 Mar;76(3):751-765
pubmed: 33128792
J Clin Immunol. 2021 Oct;41(7):1490-1501
pubmed: 34273064
Nature. 2021 Jun;594(7862):168-170
pubmed: 34108700
Front Immunol. 2020 Dec 03;11:611004
pubmed: 33343585